News
Article
FDA Approves Symbravo for Acute Treatment of Migraine With or Without Aura
Author(s):
Key Takeaways
- Symbravo, combining meloxicam and rizatriptan, is FDA-approved for acute migraine treatment, with or without aura.
- The treatment shows efficacy in reducing migraine pain and restoring normal function, lasting up to 48 hours post-dose.
Meloxicam and rizatriptan reduces migraine pain and help patients return to normal functioning with efficacy through 24 to 48 hours after a single dose for some patients.
This story is ongoing.
The FDA approved meloxicam and rizatriptan (Symbravo; Axsome Therapeutics Inc.) for the acute treatment of migraine, either with or without aura. The treatment has been shown to reduce migraine pain and help patients return to normal functioning with efficacy through 24 to 48 hours after a single dose for some patients.
The FDA approved meloxicam and rizatriptan (Symbravo; Axsome Therapeutics Inc) for the acute treatment of migraine, either with or without aura | Image Credit: goodluz | stock.adobe.com
“A significant proportion of migraine patients experience inadequate efficacy with currently available acute treatments, leading to even greater suffering, and an increased risk of worsening of migraine pain and attack frequency,” Richard B. Lipton, MD, professor of neurology and director of the Montefiore Headache Center at the Albert Einstein College of Medicine, said in a news release. “Results of multiple clinical trials demonstrate that [Symbravo] can provide rapid and long-lasting freedom from migraine pain, whether treatment is taken early in the attack while the pain is mild, or later in the attack when the pain may be severe. The approval of [Symbravo] is a long awaited and much welcomed advancement for clinicians and our patients, providing a new, meaningful treatment option.”
